Pluristem develops PLX-RAD cells for use in hematology.
HAIFA, Israel, May 7, 2013--Pluristem Therapeutics Inc. (TASE: PLTR) said it has identified its first clinical indication in the hematology field for its Placental expanded (PLX) RAD cells for the enhancement of the engraftment of hematopoietic stem cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT).
This follows Pluristem's completion of additional preclinical studies showing promising results for PLX-RAD for this indication.
According to the National Marrow Donor Program, an estimated 25,000 allogeneic bone marrow transplants are performed annually worldwide. Approximately 15 percent of these patients will either have a delay or failure to engraft the HSCs, resulting in a condition that is life threatening, expensive and often requires the continued support of the patient with blood products. PLX-RAD may be beneficial to these patients.
PLX-RAD is being evaluated by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, in models of the acute radiation syndrome (ARS).
PLX-RAD, Pluristem's second product candidate, joins PLX-PAD that is in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary hypertension.
Both product candidates are derived from placental raw material. The placenta is a very rich source for a variety of cells and Pluristem differentiates these products through the use of different cell populations combined with its proprietary 3D bioreactor manufacturing process that allows the company to change but precisely control the environment in which the cells grow. This results in a stable, consistent change to the therapeutic protein secretion profile of the cell that constitutes the difference between PLX-PAD and PLX-RAD.
Pluristem intends to develop additional PLX products by capitalizing on these unique competitive advantages.
PLX-RAD cells have been shown to have an immunomodulatory effect via the secretion of cytokines and proteins that are known to stimulate Hematopoietic Stem Cells (HSC) to enhance the production of white blood cells, red blood cells and platelets. There was also evidence of a significant improvement in the recovery of these three blood lineages in bone marrow deficient animals compared to control animals.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Cell Lines|
|Publication:||Stem Cell Business News|
|Date:||May 20, 2013|
|Previous Article:||Company to collaborate with Rutgers scientists on fat-derived stem cell research.|
|Next Article:||Cell cure awarded $1.5 m by Israeli government.|